Thyroid hormone-dependent oligodendroglial cell lineage genomic and non-genomic signaling through integrin receptors

• Published in: Frontiers in pharmacology Vol. 13; p. 934971
• Main Authors: Emamnejad, Rahimeh, Dass, Mary, Mahlis, Michael, Bozkurt, Salome, Ye, Sining, Pagnin, Maurice, Theotokis, Paschalis, Grigoriadis, Nikolaos, Petratos, Steven
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 05.09.2022
• Subjects: Akt; integrin; monocarboxylate transporter 8 (MCT8); mTOR-mammalian target of rapamycin; oligodendrocyte (OL); Pharmacology; thyroid hormone
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2022.934971

Multiple sclerosis (MS) is a heterogeneous autoimmune disease whereby the pathological sequelae evolve from oligodendrocytes (OLs) within the central nervous system and are targeted by the immune system, which causes widespread white matter pathology and results in neuronal dysfunction and neurological impairment. The progression of this disease is facilitated by a failure in remyelination following chronic demyelination. One mediator of remyelination is thyroid hormone (TH), whose reliance on monocarboxylate transporter 8 (MCT8) was recently defined. MCT8 facilitates the entry of THs into oligodendrocyte progenitor cell (OPC) and pre-myelinating oligodendrocytes (pre-OLs). Patients with MS may exhibit downregulated MCT8 near inflammatory lesions, which emphasizes an inhibition of TH signaling and subsequent downstream targeted pathways such as phosphoinositide 3-kinase (PI3K)-Akt. However, the role of the closely related mammalian target of rapamycin (mTOR) in pre-OLs during neuroinflammation may also be central to the remyelination process and is governed by various growth promoting signals. Recent research indicates that this may be reliant on TH-dependent signaling through β1-integrins. This review identifies genomic and non-genomic signaling that is regulated through mTOR in TH-responsive pre-OLs and mature OLs in mouse models of MS. This review critiques data that implicates non-genomic Akt and mTOR signaling in response to TH-dependent integrin receptor activation in pre-OLs. We have also examined whether this can drive remyelination in the context of neuroinflammation and associated sequelae. Importantly, we outline how novel therapeutic small molecules are being designed to target integrin receptors on oligodendroglial lineage cells and whether these are viable therapeutic options for future use in clinical trials for MS.